Biotech, Life Sciences, Food & Drug News from NLR
Biotech, Life Sciences, Food & Drug News from National Law Review
Agentic AI on Trial: You Be The Judge Part 1 – Medical Diagnostics | Featuring An AI Expert, a Google Cloud Exec, and a Florida Circuit Judge
When autonomous AI systems make life-and-death decisions, who is responsible when something goes wrong? In Part 1 of the Agentic AI on Trial series, Galina Datskovsky, PhD, Marina Kaganovich, and Hon. Lisa Walsh examine a hypothetical agentic AI mammography triage system designed to operate with minimal human oversight. The panel explores accountability across developers, hospitals, clinicians, and data providers—and whether new standards of care are emerging for machine decision-making. A must-listen for health tech, compliance, and healthcare operations professionals navigating the legal and operational risks of autonomous AI.
Latest on Software and AI Devices from the United Kingdom’s MHRA by Jackie Mulryne and Eleri Williams
In this article, the authors discuss new updates from the UK’s Medicines and Healthcare products Regulatory Agency on how software and artificial intelligence medical devices will be regulated in the United Kingdom after Brexit. Read and learn more!
The Blueprint for an “AI Bill of Rights”
Authors Peter Schildkraut is a co-leader of the firm's Technology, Media & Telecommunications industry team and provides strategic counsel on artificial intelligence, spectrum use, broadband, and other TMT regulatory matters. Mr. Schildkraut helps clients navigate the ever-changing opportunities and challenges of technology, policy, and law to achieve their business objectives at the US Federal Communications Commission (FCC) and elsewhere. He is the author of "AI Regulation: What You Need To Know To Stay Ahead of the Curve. James W. Kim is a nationally recognized expert in procurement law that regularly advises companies that do business with the US [...]
James Beck on the Drug & Device Law Blog: Something Both Sides Should Agree On (re Class Actions)
Senior Life Sciences Policy Analyst Reed Smith LLP Drug & Device Law Blog: Something Both Sides Should Agree On (re Class Actions) We’ll be very clear – as we have before: We don’t like most class actions. Indeed, if given our druthers, we would abolish Rule 23, as it applies to class actions for damages, altogether. But that’s not in the offing anytime soon. Today, we offer a class action decision that we think both sides, us on the defense and those on the plaintiffs side, can agree on, excluding only those responsible for the [...]